Symptoms and steroid dose adjustments following the Covid-19 vaccine in patients with adrenal insufficiency

David S. McLaren, Grace Crowe, Christine Cassidy,Irum Rasool, Mohammed Elsabbagh, Ahmad Eyadeh, Nang P. P. H. Htwe, Melinda Gerrard, Emma Ward,Saifuddin Kassim,Afroze Abbas,Ahmed Al-Qaissi,Khyatisha Seejore,Nikolaos Kyriakakis,Deirdre Maguire,Julie Lynch,Robert D. Murray

Pituitary(2024)

引用 0|浏览4
暂无评分
摘要
Background A proportion of patients with adrenal insufficiency (AI) require increases in their maintenance glucocorticoids following the Covid-19 vaccine as a result of vaccine-related symptoms or development of incipient or frank adrenal crisis. In a large cohort of AI patients, we aim to characterise symptoms, changes in glucocorticoid dosage, occurrence of adrenal crises and whether there are differences between the mRNA and adenovirus vector vaccines. Patients and methods Patients with AI of any aetiology were invited to complete a short, structured questionnaire of their experience of the Covid-19 vaccination. Results 279 of the 290 patients enrolled to this study fully completed the questionnaires. 176, 100 and 3 received the Astra Zeneca (AZ), Pfizer-BioNTech (PB) and Moderna (MD) as initial vaccine respectively; and for the second vaccine, 170, 99 and 10 received AZ, PB and MD respectively. Moderate to severe symptoms occurred in 44.8 and 39.7% after the first and second vaccines respectively, were of early onset (6.0 h, IQR 2–12 &. 6.0 h, IQR 2–24 h) and short duration (24 h, IQR 12–72 h & 26 h, IQR 12–72 h). 34.4 and 29.7% increased their maintenance glucocorticoid dose. Discussion The Covid-19 vaccines appear well-tolerated in patients with AI, with similar frequency of symptoms to that reported in the background population. The AZ vaccine leads to slightly greater post-vaccination symptom burden and need to increase glucocorticoid dosage, but this does not translate to greater adverse outcomes.
更多
查看译文
关键词
Covid-19,Vaccine,Adrenal insufficiency
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要